Pandemia Covid-19 tilanne

 Nyt on viikko 13 alullaan ja tässä on viikon 11 tilanne)

https://covid19-country-overviews.ecdc.europa.eu/index.html 

W.11

• The epidemiological picture at the pooled EU/EEA level over the past 12 months since the initial large Omicron peak has been characterised by periodic waves of infection approximately every 2–3 months. There has been a general downward trend in the height of the associated peaks in reported cases, hospitalisation, ICU admissions, and deaths in this period.

• By the end of week 11 (ending 19 March 2023), overall there were decreasing or stable trends observed in the majority of EU/EEA indicators based on pooled country data. A marginal increase was observed in hospital and ICU occupancy indicators (3% and 6%, respectively), which remain at low levels compared with their pandemic maximum as well as the maximum observed in recent peaks. The pooled COVID-19 death rate decreased compared to the previous week, with 856 deaths reported from 25 countries in the previous week.

• The number of countries reporting increasing trends has remained low, suggesting a stabilised epidemiological situation compared to the previous week.

• Among countries reporting increases in any indicator compared to the previous week, values of indicators remain low to moderate (cases below 20%, hospital indicators below 32%, and deaths below 7%) relative to the maximum reported during the pandemic.

• The following country-level trends were observed:

  • Case rates among people aged 65 years and older increased in nine of 26 countries with data. These trends have continued for the past 6–7 weeks in two of the nine countries.

  • Eight among 22 countries reporting data reported increases in the last 1–3 weeks in at least one hospital or ICU indicator.

  • Three countries reported one-week increases (3%, 7%, and 2%, respectively) in overall COVID-19 deaths. Increases in the age groups of 65–79 years and/or 80 years and above were reported by six of the 23 countries with age-specific data.

• The cumulative uptake of a first booster was 65.4% (country range: 11.3–87.1%) among adults aged 18 years and older, 84.9% (country range: 13.3–100.0%) among people aged 60 years and older and 54.7% (country range: 9.2–75.8%) in the total population. The cumulative uptake of a second booster was 17.3% (country range: 0.2–42.0%) among adults aged 18 years and older, 35.5% (country range: 0.4–86.7%) among people aged 60 years and older and 14.2% (country range: 0.2–33.6%) in the total population.

 

Sequencing volume

• Capacity of sequencing or genotyping varies greatly across the EU/EEA. ECDC uses data reported to the GISAID EpiCoV database and The European Surveillance System (TESSy) to estimate the distribution of variants in countries reporting an adequate average weekly volume of SARS-CoV-2-positive cases sequenced or genotyped (to estimate the proportion with sufficient precision for a variant prevalence of 5% or lower). Due to reporting delays in many countries, a two-week window was used, excluding the most recent week (weeks 9 to 10, 27 February to 12 March 2023).

• During this period, seven countries (Austria, Denmark, France, Germany, Ireland, Latvia and the Netherlands) reported an adequate average weekly volume of sequencing or genotyping (one with sufficient precision at a variant prevalence of 1% or lower, four with sufficient precision at a variant prevalence of >1-2.5% and two with sufficient precision at a variant prevalence of >2.5-5%), 20 countries reported an inadequate volume of sequencing or genotyping with insufficient precision at a variant prevalence of 5% and three countries did not report any data.

Distribution of variants of concern (VOCs) and variants of interest (VOIs) weeks 9-10:

• Among the seven countries with an adequate volume of sequencing or genotyping for weeks 9–10 (27 February to 12 March 2023), the estimated distribution of variants of concern (VOC) or of interest (VOI) was 
• 54.4% (49.6–66.4% from six countries) for XBB.1.5, 
• 16.8% (5.9–51.7% from seven countries) for BA.2.75, 
• 14.3% (10.5–20.3% from five countries) for XBB, 
• 11.7% (10.5–19.9% from six countries) for BQ.1,
•  1.6% (1.1–45.5% from seven countries) for BA.5,
•  1.1% (0.8–2.8% from three countries) for BA.2 
• and 0.2% (0.1–0.8%, 6 detections from three countries) for BA.4.